Medical Device Go-to-Market Strategy for FemTech

Start here: what class is this device, and which pathway gets you there? That question, not "who is our customer" or "what's our brand voice," is the one that actually sets your commercial clock. Everything else in your go-to-market plan is downstream of the answer.

For most FemTech hardware and combination device-software products, you're looking at 510(k) clearance, De Novo classification, or PMA approval. These aren't bureaucratic labels. They reflect genuine differences in risk profile, and the timelines are not abstractions you can plan around optimistically. A Harvard/NIH analysis clocked median review time for machine learning-enabled Class II devices cleared via 510(k) at 151 days in 2024. That clock starts when the submission is accepted, not filed. Add months of pre-submission work before that. De Novo ran a median 372 days in the same dataset. PMA review averages roughly 285 days for a complete submission under current MDUFA performance goals, but that figure is almost beside the point, because the pivotal clinical studies required to support a PMA add years before the review clock even starts.

What teams consistently undervalue about De Novo is what a successful outcome actually gives you structurally. Your cleared device becomes the predicate competitors must reference. So you're not just entering a market; you're writing the regulatory standard for it. Since 2021, FDA has permitted direct De Novo submissions, removing the prior requirement of first receiving a "not substantially equivalent" determination. That change meaningfully lowered friction for genuinely novel devices, and it's one of those regulatory updates that still hasn't fully registered with some founding teams.

Natural Cycles did this correctly. The company pursued FDA clearance and CE marking in tandem, designing a single evidence base that satisfied both jurisdictions simultaneously. Sequential regulatory programs leave recoverable money on the table; dual-market design recovers it.

The practical consequence: pathway selection is a product roadmap decision, not something you hand to regulatory affairs after the roadmap is already locked. It determines which clinical endpoints you need to power for, how long runway has to last before commercial launch, and which markets are even accessible at the same time. Get it wrong early and you are not adjusting a plan; you are rebuilding one with less capital than you started with and a team that's been executing in the wrong direction for months.

What Clinical Evidence a FemTech Device Actually Needs, and Why Study Design Is a GTM Decision

Most teams burn money here that they never recover. They design the pivotal study to satisfy FDA, generate data FDA accepts, receive clearance, and then discover that payers want something entirely different. The protocol is closed by then. The runway is thinner. A second study is required that nobody budgeted for.

The fix isn't scientifically complicated, but it requires organizational behavior that doesn't come naturally: reimbursement strategy and commercial strategy have to be in the room during protocol design, not waiting outside until the protocol is finalized and then reacting to it.

FDA's evidentiary threshold varies by pathway. A 510(k) can often be supported with bench testing and limited clinical data establishing substantial equivalence. De Novo and PMA require prospective clinical evidence with pre-specified endpoints, powered for safety and effectiveness. That's the regulatory layer. However, payers are looking at something else entirely: evidence the device reduces cost, prevents hospitalizations, or moves a metric they already track, like HEDIS measures. Employers want productivity data, absenteeism reduction, downstream claims impact. Designing a study without that input means arriving with data that simply doesn't answer the questions driving purchasing decisions.

The solution is to include payer-relevant and employer-relevant endpoints as pre-specified secondaries in the pivotal study. This doesn't require altering the primary FDA-facing design. It requires deciding to do it before the protocol is locked, which is a timing and organizational problem, not a scientific one.

For AI-enabled devices and SaMD products, FDA's 2024 guidance enabling Predetermined Change Control Plans adds a layer worth sitting with. PCCPs allow developers to specify in advance how an adaptive algorithm will change post-clearance, and under what validation conditions, without triggering a new submission. Commercially, this matters. However, it raises the upfront evidentiary bar, requiring algorithmic boundaries to be defined prospectively rather than refined iteratively. Some teams see that as a constraint; the smarter read is that it forces a discipline that strengthens the submission.

Germany's DiGA Fast-Track deserves serious attention for companies with global ambitions. DiGA approval requires demonstration of positive care effects, initially on a plausible basis, with real-world evidence generated during a post-approval evaluation period. So DiGA can be pursued earlier in the evidence maturation cycle, and the outcomes data produced during that evaluation period feeds directly into US payer submissions. Some companies sequence DiGA before pursuing US reimbursement precisely because it generates published outcomes data while producing early revenue in a regulated market. That's a capital-efficient strategy that not enough US-based teams have explored seriously.

The evidence constraint is also a capital constraint. Seventy-one percent of FemTech startups under six years old had not reached Series A as of 2025, per Galen Growth; for most device-stage companies, the pivotal study is the single largest pre-revenue expenditure. Study design efficiency isn't an academic consideration; it's a survival calculation.

How Reimbursement Strategy Should Be Scoped During Development, Not After Clearance

The most expensive mistake in this category is treating reimbursement as a Phase 2 problem. Teams that celebrate clearance and then spend the next twelve months discovering that their clinical evidence package doesn't match what payers need to justify coverage face a closed protocol and a budget that no longer has the same room it once did. Generating the gap-filling evidence isn't impossible; it's just harder and costlier than doing it right the first time.

Payer coverage for FemTech devices is genuinely uneven across indications. Fertility diagnostics and certain maternal monitoring modalities have an established track record of payer engagement. However, menopause management devices and pelvic floor therapeutics are navigating active coverage policy development right now, which means the landscape is shifting and the entry strategy for those indications looks different than it did two years ago. Which situation your device occupies changes everything about how you approach reimbursement. There is no generic path.

Traditional payer coverage via CPT codes and LCD or NCD policy is the most durable destination but the slowest to reach. Employer self-insured benefit carve-outs require different evidence and different contracting structures, but they move faster and don't require CPT codes. Managed care organization partnerships targeting Medicaid represent a third lane with distinct population requirements and outcomes frameworks. All three deserve parallel evaluation during development, not sequential consideration after clearance, when some of the flexibility you had earlier is gone.

The employer channel is worth particular attention as a near-term bridge. Fertility benefits adoption among large US employers reached 40% in 2024. For devices addressing fertility, maternal health, or menopause indications, employer benefits contracting is the fastest path to covered volume while traditional payer coverage policy matures. Maven's employer ROI data illustrates what payer-equivalent evidence looks like in a B2B purchasing context: a 2:1 clinical ROI, meaningful reductions in C-section rates, substantial reductions in NICU admissions. Those numbers underwrite a benefits purchasing conversation the same way a health economics dossier underwrites a payer submission. The audience is different; the evidentiary logic is the same.

Pricing architecture is where reimbursement strategy and product development become genuinely inseparable. The reimbursement pathway chosen establishes an effective price ceiling, and the device's bill of materials and gross margin targets need to be modeled against the most probable reimbursement scenario, not the most optimistic one. Building to a DTC cash-pay price point and then discovering the indication category reimburses at a substantially lower fee schedule rate is a structural problem that the sales team cannot solve. It was made in engineering, and it persists there.

Building the HCP Adoption Layer That Makes Payer and Employer Channels Work

Health system partnerships became the dominant FemTech collaboration structure in 2024, surpassing pharma partnerships for the first time in total deal volume, per Galen Growth. That shift reflects where institutional credibility is actually being built in this category. HCP adoption isn't a supplementary layer in the GTM stack; it's the mechanism that makes the downstream channels function.

It generates real-world evidence. It creates a prescribing or recommending pathway that satisfies payer coverage requirements. And it provides clinical credibility that compresses employer purchasing cycles. A device with strong HCP adoption carries a stronger payer dossier, a shorter employer sales conversation, and a more defensible competitive position, all at once, not sequentially.

Oula's partnership with Mount Sinai demonstrates what this looks like when it's executed well. Their hybrid maternity care model produced a 25% reduction in C-section rates; after 1,000 deliveries, Mount Sinai expanded to a third clinic. That outcome data is more commercially durable than anything the company could generate through a marketing campaign. After all, health system-generated evidence carries a credibility premium that no other mechanism easily replicates, because the audience for it, payers, employers, competing health systems, knows exactly how it was produced.

KOL strategy in FemTech requires subspecialty precision, and this is where a lot of teams get genuinely sloppy. OB-GYN, reproductive endocrinology, urology, and pelvic floor physical therapy have distinct influence networks, distinct publication venues, and distinct professional society structures. A single medical affairs approach rarely covers the prescriber bases that matter for a device with multiple indication touchpoints. The KOL map has to follow the indication map, not a generic "women's health" category that treats all of these audiences as interchangeable.

Investigator-sponsored study programs and pilot deployments within health system partners are among the most capital-efficient activities available to a pre-revenue device company. One clinical activity can serve FDA, payers, and employers simultaneously, but only if the data collection architecture is designed with all three audiences in mind before the pilot launches. Retrofitting data capture after the fact is expensive and, often enough, insufficient.

UnitedHealthcare's 2024 launch of a digital health contracting hub with a set of established FemTech platforms signals what scaled payer-provider integration looks like in practice. Companies that have done the HCP adoption work are positioned to enter these structured vehicles when they become available; those that haven't are starting from the beginning at precisely the moment when speed matters most.

Where DTC Fits in a Regulatory-Constrained FemTech GTM, and What It Can Realistically Do

DTC accounts for roughly 31% of FemTech market revenue in 2024, per Grand View Research. That number needs immediate context: it reflects the consumer wellness and app segment far more than cleared medical devices. The channel economics for regulated hardware and combination products are genuinely different, and the constraints aren't ones a skilled media team can optimize their way out of.

The platform censorship problem is structural and well-documented. A 2025 analysis of 159 women's health organizations found that 84% had content removed from Meta and 64% from Amazon. The clinical language that distinguishes a cleared medical device from a wellness product, the terminology that justifies a price premium and supports reimbursement eligibility, is precisely what platform policies suppress. This is a category-level constraint, and treating it as anything else leads to media budgets that evaporate without explanation.

For cleared FemTech devices, DTC works best as a patient-activation channel downstream of HCP recommendation or employer benefit enrollment. The funnel runs from physician recommendation or benefits enrollment to DTC fulfillment, not in reverse. Instead of cold acquisition via paid social, at the CAC levels the category generates and against the claims restrictions platform policies impose, teams should model this honestly before committing media budget, as that approach rarely produces unit economics that hold.

Natural Cycles is the case worth studying. The company built a meaningful consumer brand for an FDA-cleared contraceptive application by anchoring DTC messaging in the cleared indication itself and pairing it with a strong organic and earned media strategy. "FDA-cleared" became both a safety signal and a brand claim that no wellness competitor could replicate. That model works when the clearance is genuine and the indication is one consumers are actively seeking. However, not every cleared FemTech device has that attribute, and building CAC models around it when it isn't present is a planning error, not a market condition.

Content and search-optimized editorial are more durable alternatives for most regulated devices. Condition-specific content, patient community presence, and clinical explainers designed for search reach women actively researching their conditions without triggering platform ad policies. Acquisition cost compounds downward over time, and the channel doesn't disappear when a platform updates its policies unilaterally.

The real question for any device team evaluating DTC investment: what claims can actually be made, on which platforms, within the cleared indication, and does the resulting message convert at a CAC that the reimbursement ceiling established earlier in the plan can support? If the answer requires assumptions the regulatory, platform, or reimbursement environment doesn't currently support, correct the assumptions before committing the budget.

How the Funding and Partnership Landscape Shapes Which GTM Sequence Is Actually Executable

Global FemTech investment reached $2.2 billion in 2024, representing 8.5% of total digital health funding, per Galen Growth. It's a real number. However, it's also undersized relative to the clinical and regulatory capital requirements of the device pathway, particularly for companies pursuing De Novo or PMA, where pivotal study costs alone can exhaust pre-Series A runway before a single commercial conversation happens.

With 71% of FemTech startups under six years old still pre-Series A in 2025, most device-stage companies are navigating regulatory strategy, clinical study design, and reimbursement scoping on capital that wasn't sized for all three simultaneously. Discipline helps. It doesn't resolve a sequencing constraint. So the GTM framework has to accommodate the funding reality explicitly.

Pharma co-development partnerships offer one of the more elegant paths through this constraint. Bayer's selection of Impli at HLTH Europe 2024 to co-develop real-time hormone monitoring illustrates the structure: a pharma partner provides clinical study funding and institutional credibility, reducing the standalone capital requirement for the pivotal study and improving the regulatory submission profile simultaneously. These deals require concessions, typically exclusivity or equity. For a pre-Series A device company, however, the alternative is often a study that simply cannot be funded independently; concessions look different when the counterfactual is a delayed or underpowered trial.

European market entry deserves serious consideration as a first-market strategy, not a fallback for companies that couldn't make the US work. VC investment in European FemTech grew 157% year-over-year in 2024. Paired with the DiGA pathway, a European-first sequence can generate outcomes data, clinical publications, and early revenue during the post-approval evaluation period, producing the evidence base and revenue history that materially strengthens a US Series A or B pitch. For the right company profile, this is the most capital-efficient path to credible US market entry available right now.

The employer benefits channel provides a capital-light path to B2B revenue before traditional payer coverage is established. Contracting with self-insured employers requires clinical evidence and sales infrastructure, but it doesn't require CPT codes or LCD coverage policies. The buyer base is already present: 40% fertility benefits adoption among large US employers in 2024. For devices addressing fertility, maternal health, or menopause indications, employer contracting can generate revenue and outcomes data in parallel, improving the reimbursement dossier while funding operations. For some companies, it's the right primary channel for the first two years.

North America captures 65% of global FemTech investment, per Technavio's 2025 data, which means the US market presents both the most competitive funding environment and the largest accessible employer and payer base. The framework laid out here is most directly applicable to the US GTM build, where regulatory clarity is a prerequisite for investor conviction, reimbursement strategy sets the commercial ceiling, and HCP adoption is what makes every downstream channel actually function. Sequence those correctly and the capital you raise goes to market. Sequence them wrong and you spend it on commercial activity the regulatory and reimbursement environment wasn't ready to support yet.